Clinical Trial Update: Oral Nicorandil for Prevention of No Reflow Phenomenon in Anterior STEMI Patients Undergoing PPCI [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/Phase 2 trial update evaluating oral nicorandil to prevent no-reflow phenomenon in anterior STEMI patients undergoing PPCI; the study status is complete…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• No-reflow Phenomenon
• St-elevation Myocardial Infarction

Drugs mentioned

• Nicorandil (nicorandil)

Snippet

Sponsor: Ain Shams University | Conditions: No Reflow Phenomenon, Anterior STEMI | Phase 1, Phase 2 | Status: COMPLETED